Bruce Prenner, AAAAI 2022: Unmet Needs in Chronic Cough
It was a pleasure to talk with Dr. Bruce Prenner (Allergy Associates Medical Group Inc., San Diego, CA, USA) about the health burden and current stand-of-care in patients with chronic cough.
The abstract ‘Chronic Cough: Referral Sources, Etiology, Prevalence, Symptoms and Treatments In Adults A Survey of Allergy Specialists‘ was presented at AAAAI 2022, 25-28 February.
- Could you give us a brief overview of the health burden of chronic cough? (0:33)
- What is the current standard of care for chronic cough? (4:31)
Disclosures: Bruce Prenner is a consultant for ALK, Merck; has received grant/ research support from Merck, Bellus, Shionogi, Teva, Aldeyra Therapeutics; has served on advisory boards for Merck; and has participated in speaker’s bureaus for Optinose, ALK, Merck.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AAAAI annual meeting 2022.
Share this Video
Related Videos In Chronic Cough
Alan Kaplan: The IPCRG Sentinel Network and Respiratory Q&A
We were delighted to meet with Prof. Alan Kaplan (University of Toronto, Toronto, ON, Canada) to discuss the international IPCRG Sentinel Network which represents each continent and includes over 100 primary care clinicians. The IPCRG is providing answers based on published peer reviewed evidence to COVID and respiratory questions from the Sentinel Network. Questions Could […]
James Wingfield Digby, ERS 2022: Hypotonic Saline in the Diagnosis of Refractory/Unexplained Chronic Cough
Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population; however chronic cough is often unrecognized, underdiagnosed and there remain many unmet needs in its treatment. It was a pleasure to speak with Dr. James Wingfield Digby (University of Manchester, Manchester, UK) around his study […]
James Wingfield Digby, ERS 2022: Low-dose Opiates for Refractory/Unexplained Chronic Cough
Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population. touchRESPIRATORY were delighted to speak with Dr. James Wingfield Digby (University of Manchester, Manchester, UK) around the aims and design of the real world study investigating low-dose opiates in the treatment of chronic cough and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!